The Current Role of Checkpoint Inhibitors in Head and Neck Cancer

In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also suggesting the importance of policy changes and increased communication.

In an interview with Targeted Oncology, Tanya B. Dorff, MD, discussed the role of goserelin in the ever-changing treatment landscape for patients with prostate cancer.

In an interview with Targeted Oncology, Justin Taylor, MD, discussed early research on NX-2127, a BTK degrader being evaluated for the treatment of chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Yael Schenker, MD, MAS, FAAHPM, discussed the importance of palliative care and advanced care planning for patients with advanced cancers.

In an interview, Chung-Han Lee, MD, PhD, discussed the challenges, studies, and outcomes previously observed when studying adjuvant treatments for patients with renal cell carcinoma.

C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.